Skip to main content
. 2023 Jun 5;13:1156743. doi: 10.3389/fonc.2023.1156743

Figure 1.

Figure 1

Lymphoproliferation formation in a multi-region non-small cell lung cancer patient-derived model program. (A) Frequency of CD45+ xenografts in the lung TRACERx PDX program. (B) Quantification of the time elapsed between injection and xenograft detection (ns, p = 0.33, two-tailed Mann-Whitney test). Points are coloured by the prior cryopreservation status of the injected tumour material. (C) Quantification of the time elapsed between injection and experimental end point (xenograft harvest or, in the event of no xenograft formation, mouse termination; two-tailed Kruskal-Wallis test, * p < 0.05, **** p < 0.0001). Points are coloured by the prior cryopreservation status of the injected tumour material. (D) Tumour infiltrating lymphocyte score in patient tissue (NSCLC PDX vs no growth, p = 0.258; NSCLC PDX vs CD45+, p > 0.99; No growth vs CD45+, p > 0.99; Kruskal-Wallis test).